Castle Biosciences, Inc. (NASDAQ:CSTL) Stock Has Average Target Price of $42.00

Posted by Stanley Muller on Oct 16th, 2026

Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the ten research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $42.00.

A number of research analysts have weighed in on the stock. Roth Capital assumed coverage on shares of Castle Biosciences in a research report on Wednesday, June 24th. They set a “buy” rating and a $40.00 price objective on the stock. Robert W. Baird set a $36.00 price objective on shares of Castle Biosciences in a research note on Friday, July 31st. BTIG Research lifted their price target on Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Wall Street Zen upgraded shares of Castle Biosciences from a “hold” rating to a “buy” rating in a research note on Saturday, September 26th. Finally, Weiss Ratings raised Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st.

Check Out Our Latest Research Report on Castle Biosciences

Castle Biosciences Price Performance

CSTL stock opened at $33.80 on Friday. The stock’s 50 day simple moving average is $33.56 and its 200 day simple moving average is $26.82. The company has a quick ratio of 5.85, a current ratio of 6.04 and a debt-to-equity ratio of 0.02. Castle Biosciences has a 12-month low of $17.72 and a 12-month high of $44.28.

Castle Biosciences (NASDAQ:CSTL – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.34. The company had revenue of $99.86 million for the quarter, compared to analysts’ expectations of $86.23 million. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%. Research analysts expect that Castle Biosciences will post -1.29 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Castle Biosciences news, COO Kristen Oelschlager sold 4,153 shares of the company’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $35.95, for a total value of $149,300.35. Following the sale, the chief operating officer owned 13,356 shares of the company’s stock, valued at approximately $480,148.20. This represents a 23.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Tobin Juvenal sold 3,288 shares of the business’s stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $33.64, for a total transaction of $110,608.32. Following the completion of the sale, the insider owned 48,719 shares in the company, valued at $1,638,907.16. This represents a 6.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 206,946 shares of company stock valued at $6,642,699. 6.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Castle Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in CSTL. BlackRock Inc. purchased a new position in Castle Biosciences in the 2nd quarter worth $78,513,000. Summit Partners Public Asset Management LLC grew its holdings in Castle Biosciences by 164.7% in the fourth quarter. Summit Partners Public Asset Management LLC now owns 1,058,725 shares of the company’s stock worth $41,184,000 after purchasing an additional 658,725 shares during the period. Jefferies Financial Group Inc. purchased a new stake in shares of Castle Biosciences in the 2nd quarter worth approximately $15,440,000. AIGH Capital Management LLC bought a new stake in Castle Biosciences in the second quarter worth $13,001,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Castle Biosciences in the second quarter worth $7,912,000. 92.60% of the stock is owned by institutional investors.

Castle Biosciences Company Profile

(Get Free Report)

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to provide personalized information for patients with cancer and other serious diseases. Its products analyze biological characteristics in tissue samples to help physicians assess disease risk, guide treatment decisions and support patient management.

The company’s portfolio includes diagnostic tests for skin cancers, such as DecisionDx-Melanoma for assessing metastatic risk in patients with cutaneous melanoma and DecisionDx-SCC for evaluating metastatic risk in certain cases of cutaneous squamous cell carcinoma.